0000899243-21-035130.txt : 20210903
0000899243-21-035130.hdr.sgml : 20210903
20210903163111
ACCESSION NUMBER: 0000899243-21-035130
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210901
FILED AS OF DATE: 20210903
DATE AS OF CHANGE: 20210903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOLMLUND JON T
CENTRAL INDEX KEY: 0001227367
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39114
FILM NUMBER: 211236950
BUSINESS ADDRESS:
STREET 1: 2292 FARADAY AVE
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: 7609319200
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563577
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461454898
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-725-1500
MAIL ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-01
0
0001563577
Galera Therapeutics, Inc.
GRTX
0001227367
HOLMLUND JON T
C/O GALERA THERAPEUTICS, INC.,
2 W LIBERTY BLVD #100
MALVERN
PA
19355
0
1
0
0
Chief Medical Officer
Common Stock
2021-09-01
4
M
0
47756
2.43
A
47756
D
Common Stock
2021-09-01
4
S
0
47756
8.4701
D
0
D
Stock Option
2.43
2021-09-01
4
M
0
47756
0.00
D
2026-03-31
Common Stock
47756
61142
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2019.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.11 to $9.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option has fully vested and is currently exercisable.
/s/ Christopher Degnan, Attorney-in-Fact for Jon T. Holmlund
2021-09-03